A Double Blinded, Randomized, Controlled Investigation of Taurolidine-citrate/Heparin Catheter Lock Solution Versus Heparin in Patients on Home Parenteral Nutrition With Previously Proven High Risk of Catheter Related Blood Stream Infections

Trial Profile

A Double Blinded, Randomized, Controlled Investigation of Taurolidine-citrate/Heparin Catheter Lock Solution Versus Heparin in Patients on Home Parenteral Nutrition With Previously Proven High Risk of Catheter Related Blood Stream Infections

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Taurolidine (Primary) ; Heparin
  • Indications Bacterial infections; Embolism and thrombosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 Primary endpoint (Mean number of catheter related blood stream infections(CRBSI)/ 1000 catheter days in each group) has been met, according to the Results published in the American Journal of Clinical Nutrition.
    • 01 Sep 2017 Status changed from active, no longer recruiting to completed, according to the results published in the American Journal of Clinical Nutrition.
    • 01 Sep 2017 Results published in the American Journal of Clinical Nutrition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top